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Abstract
The dysferlin deficient SJL/J mouse strain is commonly used to study dysferlin deficient myopathies. Therefore, we
systematically evaluated behavior in relatively young (9–25 weeks) SJL/J mice and compared them to C57BL6 mice to
determine which functional end points may be the most effective to use for preclinical studies in the SJL/J strain. SJL/J mice
had reduced body weight, lower open field scores, higher creatine kinase levels, and less muscle force than did C57BL6
mice. Power calculations for expected effect sizes indicated that grip strength normalized to body weight and open field
activity were the most sensitive indicators of functional status in SJL/J mice. Weight and open field scores of SJL/J mice
deteriorated over the course of the study, indicating that progressive myopathy was ongoing even in relatively young (,6
months old) SJL/J mice. To further characterize SJL/J mice within the context of treatment, we assessed the effect of fasudil,
a rho-kinase inhibitor, on disease phenotype. Fasudil was evaluated based on previous observations that Rho signaling may
be overly activated as part of the inflammatory cascade in SJL/J mice. Fasudil treated SJL/J mice showed increased body
weight, but decreased grip strength, horizontal activity, and soleus muscle force, compared to untreated SJL/J controls.
Fasudil either improved or had no effect on these outcomes in C57BL6 mice. Fasudil also reduced the number of infiltrating
macrophages/monocytes in SJL/J muscle tissue, but had no effect on muscle fiber degeneration/regeneration. These
studies provide a basis for standardization of preclinical drug testing trials in the dysferlin deficient SJL/J mice, and identify
measures of functional status that are potentially translatable to clinical trial outcomes. In addition, the data provide
pharmacological evidence suggesting that activation of rho-kinase, at least in part, may represent a beneficial
compensatory response in dysferlin deficient myopathies.
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Introduction
Limb Girdle Muscular Dystrophy type 2B (LGMD2B) is caused
by the loss of function mutations in the dysferlin gene [1].
Dysferlin is primarily expressed in skeletal and cardiac muscle, but
also in monocytes, macrophages, and other tissues where it is
localized to cytoplasmic vesicles and the cell membrane [2,3].
Dysferlin appears to be involved in membrane fusion and
trafficking, as well as repair processes [4]. LGMD2B is a late
onset (teens/young adults) muscle disease that is characterized by
progressive symmetrical muscle weakness, and notably aggressive
immune/inflammatory pathology. Muscle biopsies typically show
marked inflammatory cell infiltration, consisting primarily of
macrophages/macrophage activation markers (HLA-DR, HLA-
ABC, CD86), CD8
+ cytotoxic T cells, and CD4
+ T cells, together
with muscle fiber degeneration/regeneration [5,6].
SJL/J mice have an in-frame deletion of 171 bp in the 39 splice
junction of exon 45 of dysferlin [7,8]. They develop spontaneous
myopathy that is associated with obvious muscle inflammation as
they age. Together, these features make SJL/J mice a genetic
homologue of human dysferlin deficient myopathies. Inflammatory
changes in SJL/J mouse muscles typically begin around 4–6 weeks
of age, and are characterized by infiltration of activated macro-
phages, followed by CD4+ T cells [8–10]. At 6 months, the infiltrate
consists primarily of macrophages, along with some muscle fiber
necrosis. By 16 months, muscle fibers completely degenerate and
are replaced by fat and collagen [10,11]. Although biochemical and
histological features of the SJL/J strain have been relatively well
documented, the functional and behavioral symptoms of the
progressing myopathy have not been fully characterized, particu-
larly during the early stages of disease, which are most likely to be
useful for evaluation of potential treatment strategies.
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from LGMD2B patients and SJL/J mice display enhanced
phagocytic activity both in the unstimulated environment, as well
as in response to inflammatory cytokines [4]. Expression of the Rho
family GTPases RhoA, Rac1 and Cdc 42, which are involved in
monocyte phagocytosis, are also increased in dysferlin-deficient
immune cells relative to controls. In addition, markers of dendritic,
T-cell, and macrophage activation (CD86, HLA-ABC, and HLA-
DR) are expressed in LGMD2B muscle. These observations led us
to propose that an overly aggressive inflammatory response in
dysferlin deficient muscle may play a role in the progression of
muscle disease [9]. Rho proteins are ubiquitous and have been
widely studied for their potential contribution to many cellular
functions, including motility and vesicular trafficking [12–14]. The
consequences of Rho activation mainly depend on its downstream
effectors, the Rho-kinases (ROCK) [15–16]. Rho-kinases exist as 2
isoforms:ROKa/ROCKIIorROKb/ROCKI,whichhave many
overlapping functions, although isoform specific differences are
beginning to emerge. Activation of the ROCK pathway is a critical
event in a number of inflammatory cell activities, including
proliferation, phagocytosis, production of pro-inflammatory cyto-
kinesandinthe activationofNF-kB[16–18].Thus, inhibition ofthe
ROCK pathway limits damage in models of inflammation, or in
diseases that involve a significant inflammatory response compo-
nent,suchasasthma,sepsis,arthritis,and multiplesclerosis [19–22].
Indeed,the ROCK inhibitor fasudil has already been used clinically
for several of these conditions. The major metabolite of fasudil,
hydroxyfasudil, is an equipotent, relatively selective inhibitor of
ROCKs-1and -2,andshows100 fold higherspecificityforROCK-
2 than for protein kinase C or myosin light chain kinase [23,24].
We recently determined which behavioral outcomes may be the
most reliable for drug efficacy studies in Duchenne muscular
dystrophy using mdx mice [25]. The present study undertakes a
similar evaluation in the SJL/J mouse model of dysferlin
deficiency. SJL/J mice were temporally evaluated and compared
to C57BL6 control mice using several common behavioral
measures, including grip strength (forelimb and hindlimb), open-
field (digiscan) activity and rotarod performance. In vitro muscle
force, serum creatine kinase, and histology were also examined.
Further, we also performed a drug efficacy study with the Rho-
kinase inhibitor fasudil, using these same parameters. Fasudil was
selected for evaluation because of the established role of Rho-
kinases in macrophage/monocyte activation and the potential
involvement of these inflammatory cells in the progression of
dysferlin deficient myopathies.
Materials and Methods
Experimental design
Six week-old male SJL/J (n=30) and C57BL/6 mice (n=30)
weighing 20–25 g were obtained from the Jackson Laboratories
(Bar Harbor, ME). All mice were housed in an individually vented
cage system under controlled 12-h light/dark cycle with free access
to feed and water. Animals were handled according to our
Institutional Animal Care and Use Committee guidelines at
Children’s National Medical Center (Approved protocol # 214-
07-01) and Washington DC Veterans Affairs Medical Center
(Approved protocol # 1079). Each strain of mice was randomly
separated into 2 groups, untreated (n=15) and fasudil treated
(n=15) respectively. Untreated mice were given normal water,
whereas fasudil treated mice were given fasudil ad lib via drinking
water for 16 weeks at a dose of 75 mg/kg body weight starting at 9
weeks of age. This dosage is based on previously published oral
dosages [20,26,27]. To verify the actual drug dosage, water
consumption was assessed by measuring the amount of water
consumed per cage, and dividing this by the number of animals
present. Both treated and untreated SJL/J mice consumed more
water (mean 6 SE) (4.960.27 ml) per day, than did C57BL6 mice
(3.360.08 ml), therefore, the actual concentration of fasudil in the
water was adjusted based on the average water consumption for
each strain. Treated mice in both strains initially drank less during
the first week of treatment, but this resolved by the second week.
Functional and behavioral data were obtained at 9, 17 and 25
weeks of age. The in vitro muscle function tests, serum creatine
kinase levels, and histological evaluations were conducted at 25
weeks of age as described below.
Functional tests
Grip strength was assessed using a grip strength meter (GSM)
(Columbus instruments, Columbus, Ohio) as detailed previously
[25]. All the mice were acclimatized on the GSM for 3 consecutive
days, at least 1 week before actual data collection. Five successful
forelimb and hindlimb strength measurements were recorded in
the morning hours over a 5-day period by an investigator blinded
to treatment. The maximum grip strength values of each day were
used for subsequent analysis; the data were normalized to body
weight and expressed as kilogram force/kg (KGF/kg).
Overall motor coordination was measured with a rotarod
apparatus as described previously with slight modifications [25].
Mice were acclimatized on the rotarod (Ugo Basile, VA, Italy) for
a period of four sessions for 2 days prior to the data collection. To
perform the test, mice were placed on a rod rotating at a speed of
10 rpm. A maximum speed of 54 rpm was obtained within 4
minutes and the test was continued to a maximum of 3 minutes or
until the mice fell from the rod. Data was collected by an
investigator blinded to treatment twice a day, with a 2-h interval
between the sessions, for 3 consecutive days. The time that a
mouse stayed on the rod was recorded and the mean data were
expressed as latency to fall (sec) for each mouse.
Open field behavioral activity was measured using an open field
digiscan apparatus (Omnitech Electronics, Columbus, OH) as
described previously [25]. All mice were acclimatized to the
apparatus before actual data collection. The actual data were
collected every 10 min over a 1-h period each day for 4
consecutive days and the results were expressed as mean 6 SE
for all behavioral parameters [25].
Histological evaluation
All mice were sacrificed at 25 weeks of age, and the tibialis anterior
(TA) and quadriceps femoris muscles were collected for hematoxylin
and eosin staining (H&E) and immunohistochemistry, respectively.
The muscles were kept in formalin for H&E staining or embedded in
Tissue-Tek (West Chester, PA) and flash frozen in liquid nitrogen
chilled isopentane for immunohistochemistry. Serum was also
acquired from these mice to estimate the creatine kinase levels. For
hemotoxylin and eosin staining, the TA of fasudil treated (n=5)and
untreated (n=5) mice were collected and stained as previously
described [25]. For quantification, 5 non-overlapping representative
fields of the stained tissue sections were imaged under a light
microscope (40X) and a digital image for each field was obtained
using computer software (Olympus America Inc., Center Valley,PA).
Thedigitalimageswere loaded into Image J(NIH) with an additional
plug-in to count cells. Briefly, total fibers present; total fibers with
central nuclei; regenerating fibers (basophilic fibers); degenerating
fibers; and inflammation (defined as an interstitial group of .10
smaller inflammatory cell dark blue nuclei in a high power field) were
assessed. Quantitative procedures were performed as detailed
previously [25].
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macrophages the frozen sections of quadriceps femoris muscle
from fasudil treated (n=4) and untreated (n=4) SJL/J mice were
stained with rat anti-mouse F4/80 antibody (Serotec, Oxford,
UK). F4/80 antibody served as a marker for infiltrating
monocytes, and macrophages. Anti-rat horseradish peroxidase
(DAKO, Carpinteria, CA) was used as a secondary antibody.
Isotype-matched mouse immunoglobulins were used as negative
controls. Three non-overlapping fields of the entire tissue section
were imaged (20X) and quantified for the presence of inflamma-
tory foci. The foci were defined as aggregates of F4/80
+
macrophages and monocytes.
In vitro force measurement
The EDL and soleus muscles of the right hindlimbs were
removed from anesthetized mice, and were placed vertically in a
bath containing buffered mammalian Ringer solution (25uC) and
bubbled with 95% O2–5% CO2. The distal tendon of the muscle
was tied securely to the lever arm of a servomotor/force
transducer (model 305B, Aurora Scientific) and the proximal
tendon was fixed to a stationary post in the bath. The muscles
were stimulated between two stainless steel plate electrodes. At
optimal muscle length, the force developed was measured during
trains of stimulation (1000 ms for soleus, and 300 ms for EDL
muscles) with increasing frequencies till the highest plateau was
achieved. The force generated to obtain the highest plateau was
established as the maximal force generated by the muscle and is
expressed in milli Newton (mN). Further, the specific force was
obtained by dividing the maximal force with the physiologic cross
sectional area of muscle and is expressed as kN/m
2. The
physiologic cross sectional area was calculated by dividing the
muscle mass with the fiber length and density (1.056 kg/m
3)o f
muscle tissue. The fiber length is established as 0.45 and 0.71 of
muscle length for the soleus and EDL muscles respectively [28].
Creatine kinase determination
Blood (250 ml) was collected into eppendorf tubes by cardiac
puncture immediately after euthanasia and was allowed to clot at
room temperature prior to centrifugation and serum collection.
Creatine kinase (CK) determination was performed according to
the manufacturer’s instructions using a standard spectrophoto-
metric method [29,30]. Absorption at 340 nm was measured every
minute for 2 minutes at 37uC to calculate enzyme activity.
Duplicate measurements were done on each serum sample, and
the data were expressed as units per liter.
Statistical analysis
As the behavioral data were not normally distributed we
performed non-parametric tests for the statistical analysis. The
drug effects (drug vs untreated controls) of each strain type were
compared at each time point using the Wilcoxon rank sum test. To
assess the effect of drug treatment and time on individual behavioral
outcomes over the 9–25 week study period, the raw data for each
test were ranked and then 2-way repeated measures ANOVA with
factor A as drug and factor B as time was used for statistical
assessment. The histological and in vitro force measurements were
compared between treated and untreated wild-type or SJL/J mice
at each time point using student’s t-test for independent samples. A
value of p,0.05 was considered significant. Power values were
determined using estimates from each mouse strain and assuming
an N of 10 per group. The effect size necessaryto detect a significant
association with an N of 10 was determined by using C57BL6 as the
reference group and calculating the effect size that would produce a
significant difference.
Results
Phenotypic differences between dysferlin deficient SJL/J
and C57BL6 control mice
SJL/J mice generally weighed less than C57BL6 mice at all ages
and they gained less weight overall during the course of the study
(C57BL6 vs SJL/J: mean 6 SEM 11.1760.73 vs 5.5960.59;
p,0.0001, Wilcoxon Rank Sum test) (Table 1). Since body weight
may influence grip strength, the grip strength data were
normalized to body weight. Thus the normalized forelimb (NFL)
grip strength was greater in SJL/J mice at all ages than in C57BL6
mice (Table 1). However, both strains showed proportional
decreases in NFL grip strength over the course of the study.
Normalized hindlimb (NHL) grip strength was also higher in SJL
mice than in C57BL6 mice at older ages (17 and 25 weeks). There
were no significant differences in rotarod performance between
mouse strains (Table 1).
A number of behavioral differences between SJL/J and
C57BL6 mice were detected in the open field measurements
(Table 2). In these tests, SJL/J mice performed significantly worse
than C57BL6 mice by nearly all measures. They displayed less
horizontal or vertical activity, traveled a shorter total distance, and
spent more time resting in the open field than did C57BL6
controls. Moreover, for SJL/J mice, scores on all these measures
were significantly lower at 25 wks than at 9 wks, whereas scores
for C57BL6 mice were unchanged over time. Thus, all these tests
detected deterioration in performance in the SJL/J mice. All the
open field measurements had relatively high power, although
effect sizes varied widely across specific outcomes. Rest time
appears to have been the most sensitive indicator as reflected in an
effect size of 2%–3.3% (Table 2).
Weights of selected muscles, and the heart and spleen of
C57BL6 controls and SJL/J mice were measured at 25 weeks of
age (Table 3). Notably, the weight of the Soleus in SJL/J mice was
half that observed in C57BL6 mice, whereas the weight of the
SJL/J spleen was nearly double that of C57BL6 mice. No
significant differences were observed in the weights of extensor
digitorum longus (EDL) or tibialis anterior muscle.
In vitro force contractions were measured in isolated EDL and
Soleus muscles of SJL/J and C57BL6 mice at 25 weeks of age. The
maximal and specific force of both muscles was significantly less in
SJL/J mice compared with C57BL6 (Figure 1). The mean CK
value (U/L) of SJL/J mice (826.06135.9) was higher (p,0.05)
than in C57BL6 mice (378.8699.21).
Effect of fasudil treatment on the behavioral
phenotype(s) of dysferlin deficient (SJL/J) and control
(C57BL6) mice
Treatment with fasudil decreased both the NFL and NHL grip
strength of SJL/J mice compared to untreated controls (Table 4).
Although only the 17 wk NFL individual time comparison between
treated and untreated is statistically different by the Wilcoxon rank
sum test, the 2-way ANOVA comparison of all times in treated vs.
untreated SJL/J mice indicated a significant effect of both drug
(p=0.0278) and time (p,0.0001) on NFL performance between the 2
groups from 9 to 25 wks of age. Similarly, NHL scores were
significantly less at both 17 and 25 wks in fasudil treated vs untreated
SJL/J controls, and the 2-way ANOVA comparison for NHL scores
of all times in treated vs untreated SJL/J mice indicated significant
effects of both drug (p=0.0002) and time (p,0.0001) from 9 to
25 wks of age. Fasudil did not have any effect on rotarod
performance in SJL/J mice (Table 4).
While most of the open field tests showed no effect of fasudil
treatment on outcome, all the tests indicated a significant decline in
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controls (2-way ANOVA for all tests, effect of time, p,0.0001)
(Table 5). The only open field test to show a significant negative effect
of fasudil was the horizontal activity score, which indicated that
fasudil treatment resulted in significantly less horizontal activity
compared to untreated SJL/J controls at 25 wks of age.
There was little evidence to suggest that fasudil treatment
worsened outcomes in C57BL6 mice as it did in the SJL/J strain
(Supplementary Tables S1 and S2). While fasudil treatment did
result in significantly worse NHL grip strength compared to
untreated controls at 25 wks of age, it also increased body weight
at this time point. Moreover, it improved horizontal activity scores
Table 2. Comparison of open field behavioral activity of C57BL6 and SJL/J mice at 9, 17 and 25 weeks of age.
Measurement Age (wk) N
1
C57BL/6
Mean ± SE N
1
SJL/J
Mean ± SE p-value
*
Power with
N=10
per group
Effect size necessary
with N=10 per
group‘
Horizontal activity 9 15 885.1655.7 15 523.5619.4 ,0.0001 99.9% 32.3%
17 14 882.6674.3 13 389.8631.4 ,0.0001 99.9% 41.8%
25 14 1008.0686.0 13 405.5619.1 ,0.0001 99.9% 42.3%
Total distance (cm) 9 15 194.8619.5 15 85.968.0 ,0.0001 98.8% 51.1%
17 14 152.9625.5 13 32.965.5 0.0002 97.4% 82.7%
25 14 185.0633.0 13 39.3611.3 0.0004 94.3% 88.5%
Rest time (s) 9 15 576.462.2 15 590.660.9 ,0.0001 99.8% 2.0%
17 14 581.463.1 13 595.860.7 0.0002 97.5% 2.6%
25 14 577.863.8 13 595.661.2 0.0002 96.7% 3.3%
Vertical activity 9 15 20.562.2 15 7.661.0 ,0.0001 99.3% 54.3%
17 14 15.761.8 13 3.360.9 ,0.0001 99.9% 55.9%
25 14 19.462.9 13 3.260.8 ,0.0001 99.6% 73.9%
All data are expressed as mean 6 SE;
1Number of animals per group;
*p-values are from Wilcoxon rank sum at each time point;
‘Effect size between C57BL/6 and SJL/J mice that is necessary to conclude a significant difference.
doi:10.1371/journal.pone.0012981.t002
Table 1. Comparison of weight, grip strength, and rotarod performance of C57BL6 and SJL/J mice at 9, 17 and 25 weeks of age.
Measurement Strain 9 weeks 17 weeks 25 weeks
Overall
p-value
*
Significantly
different means
N
1 Mean ± SEM N
1 Mean ± SEM N
1 Mean ± SEM
Weight (gm) C57BL/6 15 21.8760.31
a,b 14 29.4760.69
a,c 14 32.9660.91
b,c ,0.0001
a p,0.001
b p,0.001
c p=0.002
SJL/J 15 20.6060.21
a,b 13 22.8760.49
a,c 13 26.1360.55
b,c ,0.0001
a p=0.002
b p,0.001
c p,0.001
NFL
2 C57BL/6 15 4.8160.08
a,b 14 3.3160.10
a 14 3.2460.12
b ,0.0001
a p,0.001
b p,0.001
SJL/J 15 6.1960.24
a 13 6.7360.31
b 13 5.0660.26
a,b 0.0004
a p=0.014
b p,0.001
NHL
2 C57BL/6 15 11.3960.17
a,b 14 8.9860.25
a 14 8.8860.30
b ,0.0001
a p,0.001
b p,0.001
SJL/J 15 10.8360.18
a 13 14.2560.47
a,b 13 11.0060.41
b ,0.0001
a p,0.001
b p,0.001
Rotarod (s)
3 C57BL/6 15 98.8610.2 14 79.068.5 14 70.467.8 NS
4
SJL/J 15 88.967.4 13 73.566.7 13 87.367.3 NS
4
All data are expressed as mean 6 SE,
1Number of animals per group,
2NFL (Forelimb) and NHL (Hindlimb) grip strength data are normalized to body weight and are expressed in kilogram force per kilogram (KGF/kg),
3Rotarod, the length of time in seconds that mice stayed on the rotarod.
*p-values are from Wilcoxon rank sum test at each time point,
4NS, not statistically significant.
a, b, cindicate the p value for the significant differences between means with the same letter (eg a vs a etc.).
doi:10.1371/journal.pone.0012981.t001
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for 9–25 wks of age, drug effect (p=0.01). The significant
difference between treated and untreated at 9 wks does not reflect
a drug effect, because the 9 wk score is the baseline score obtained
before initiation of treatment. Fasudil appeared to increase
distance traveled and vertical activity in the open field, as well
as reduce rest time, however such changes were only observed at
17 wks of age, rather than over the entire study (9–25 wks), or at
both 17 and 25 wks. The reasons for this change in behavioral
activity at 17 wks are presently unclear.
Effect of fasudil treatment on muscle force, histology and
inflammation in dysferlin deficient (SJL/J) and control
(C57BL6) mice
Fasudil treatment did not alter the maximal (Figure 2, A and B)
or specific (Figure 2, E and F) force of EDL muscle in either mouse
strain. However, fasudil treatment significantly reduced the
maximal force of soleus muscle in SJL/J mice (Figure 2, C), but
had no effect on the maximal force of soleus muscle of C57BL6
mice (Figure 2, D). No significant differences were observed in the
specific force of soleus muscle between treated or untreated groups
Table 3. Weights of muscles, heart and spleen of C57BL6 and SJL/J mice at 25 weeks of age.
Name C57BL6 SJL/J
p-value
*
(Weight)
p-value
#
Normalized
Weight
1 Normalized
2 Weight
1 Normalized
2
Soleus 10.4760.74 0.3360.02 5.0660.14 0.1960.01 ,0.0001 ,0.0001
EDL
3 12.4461.04 0.3960.03 10.5960.19 0.3960.01 0.1174 0.9138
TA
4 57.1164.60 1.7960.13 53.3760.86 1.9960.06 0.4649 0.2040
Gastrocnemius 141.0064.66 4.4560.14 137.6062.37 5.1060.09 0.5452 0.0010
Heart 130.2063.65 4.1060.08 139.3063.65 5.1760.15 0.0929 ,0.0001
Spleen 76.4661.70 2.4260.07 170.7066.36 6.2860.56 ,0.0001 ,0.0001
All data are expressed as mean 6 SE;
1Raw weight of the muscle expressed in milligrams (mg);
2Raw weight of muscle normalized to respective bodyweight;
3Extensor digitorum longus;
4Tibialis anterior;
*p-values for student’s t-test comparison of raw muscle weights between C57BL6 and SJL/J mice;
#p-values for student’s t-test comparison of normalized weights between C56BL6 and SJL/J mice.
doi:10.1371/journal.pone.0012981.t003
Figure 1. Maximal and specific force of extensor digitorum longus (EDL) and soleus muscles of SJL/J and C57BL6 mice: At 25 weeks of
age SJL/J (n=5/group) and C57BL6 (n=8/group) mice were sacrificed and in vitro muscle function tests were performed for EDL (A, C) and soleus (B,
D) muscles. Shown are the values obtained for maximal force (mN) (A & B), specific force (kN/m
2) (C & D). Values were compared using Student’s t-test
for independent samples, where *=p,0.05.
doi:10.1371/journal.pone.0012981.g001
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of fasudil treated and untreated SJL/J mice were 10566238.8 and
826.06135.9, respectively. However, these differences were not
statistically significant.
There was no difference in the mass of the spleen between
untreated or fasudil treated mice in either the SJL/J or C57BL6
strains.Values(mean 6SE)forthe normalized spleen mass forSJL/J
untreated and fasudil treated groups were 6.2860.56 and 6.5960.73
respectively. The normalized spleen mass for C57BL6 untreated and
fasudil treated groups were 2.4260.07 and 2.3160.11 respectively.
Fasudil treatment did not significantly change a number of
histological features observed in the TA muscle of SJL/J mice
(supplementary Table S3). For example, fasudil did not alter the total
number of muscle fibers, the number of degenerating or regenerating
fibers, or the number of central nuclei. However, the quadriceps
femoris of fasudil treated SJL/J mice displayed a significant reduction
in the number of inflammatory foci compared to untreated SJL/J
mice (Figure 3). There was no notable difference in the location of
inflammatory infiltrates between treated vs control animals. Histo-
logical evaluation was not performed for C57BL6 mice.
Table 4. Comparison of weight, grip strength, and rotarod performance of fasudil treated and untreated SJL/J mice at 9, 17, and
25 weeks of age.
Measurement Age (wk) N
1
Treated
Mean ± SEM N
1
Untreated
Mean ± SEM p-value
*
Power with N=10 per
group
Weight (gm) 9 15 20.5360.34 15 20.6060.21 NS
2 5.2%
17 12 24.4460.41 13 22.8760.49 0.0179 59.0%
25 11 26.8160.67 13 26.1360.55 NS
2 11.1%
NFL
3 9 15 6.0860.19 15 6.1960.24 NS
2 6.2%
17 12 5.7460.23 13 6.7360.31 0.0339 63.2%
25 11 4.3260.15 13 5.0660.26 NS
2 59.5%
NHL
3 9 15 10.5260.25 15 10.8360.18 NS
2 13.2%
17 12 12.1760.41 13 14.2560.47 0.0065 84.2%
25 11 9.6960.29 13 11.0060.41 0.0257 66.2%
Rotarod (s)
4 9 15 90.666.2 15 88.967.4 NS
2 5.3%
17 12 75.965.1 13 73.566.7 NS
2 5.8%
25 11 68.268.7 13 87.367.3 NS
2 34.4%
All data are expressed as mean 6 SEM;
1Number of animals per group;
2NS, not statistically significant;
3NFL (Forelimb) and NHL (Hindlimb) grip strength data are normalized to body weight and are expressed in kilogram force per kilogram (KGF/kg);
4Rotarod, the length of time in seconds that mice stayed on the rotarod;
*p-values are from Wilcoxon rank sum tests at each time point.
doi:10.1371/journal.pone.0012981.t004
Table 5. Comparison of open field behavioral activity of fasudil treated and untreated SJL/J mice at 9, 17, and 25 weeks of age.
Measurement Age (wk) N
1
Treated
Mean ± SEM N
1
Untreated
Mean ± SEM
Power with N=10 per
group
Horizontal activity 9 15 549.8636.4 15 523.5619.4
a 8.0%
17 12 358.8624.9 13 389.8631.4
a 10.6%
25 11 306.5632.1 13 405.5619.1
b 69.4%
Total distance (cm) 9 15 101.3611.7 15 85.968.0
a 14.3%
17 12 29.864.2 13 32.965.5
a 6.8%
25 11 19.263.4 13 39.3611.3
a 32.1%
Rest time (s) 9 15 589.061.3 15 590.660.9
a 15.0%
17 12 596.360.5 13 595.860.7
a 6.5%
25 11 597.560.5 13 595.661.2
a 29.4%
Vertical activity 9 15 10.261.8 15 7.661.0
a 16.8%
17 12 3.360.7 13 3.360.9
a 5.0%
25 11 1.560.5 13 3.260.8
a 39.1%
All data are expressed as mean 6 SEM;
1Number of animals per group;
aIndicates no significant difference between treated and untreated groups;
bIndicates significant difference between treated and untreated groups (Wilcoxon rank sum test, p=0.0138).
doi:10.1371/journal.pone.0012981.t005
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PLoS ONE | www.plosone.org 6 September 2010 | Volume 5 | Issue 9 | e12981Figure 2. Effect of fasudil on extensor digitalis longorum (EDL) and soleus muscle force: At 25 weeks of age, in vitro muscle function tests
were performed on EDL (A, B, E, F) and soleus (C, D, G, H) muscles to determine the affect of fasudil treatment on muscle force in C57BL6 (B, F, D, H)
and SJL/J (A, E, C, G) mice. Shown are the graphs for maximal force (MF) (mN) (A–D) and specific force (SF) (kN/m
2) (E–H) for soleus and EDL of each
strain. Treatment groups of each strain were compared using student’s t-test for independent samples. *p=,0.05 by Student’s t-test comparisons.
doi:10.1371/journal.pone.0012981.g002
Figure 3. Effect of fasudil on inflammatory foci: Representative sections of untreated (A) and fasudil treated (B) (n=4/group) quadriceps
femoris muscle of SJL/J mice sacrificed at 25 weeks of age. Frozen sections of quadriceps femoris were stained with rat anti-mouse F4/80 (Serotec,
Oxford, UK) primary antibody. Anti-rat horse-radish peroxidase (DAKO, Carpinteria, CA) was used as a secondary antibody. Three non-overlapping
fields of the entire tissue section were imaged (20X) and quantified. Data were graphed (mean 6 SEM) and the groups were compared using
student’s t-test for independent samples, where *p,0.05 by Student’s t-test comparison.
doi:10.1371/journal.pone.0012981.g003
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This study assessed phenotyping and preclinical evaluation
methods for dysferlin deficient SJL/J mice, focusing on behavioral
(grip strength, open field, and rotarod), functional, (in vitro force
measurements on isolated muscle) and histological measurements.
Significant differences in body weight, grip strength, behavioral
activity and in vitro force contraction measurements between
C57BL6 and SJL/J mice were observed. Moreover, a progressive
deterioration of functional performance in SJL/J mice was
detectable from 9 to 25 weeks of age, which is relatively early in
the development of spontaneous myopathy. Treatment with the
rho-kinase inhibitor fasudil did not ameliorate the dysferlin
deficient phenotype. Rather, fasudil treatment resulted in reduced
grip strength (both fore limb and hind limb) and reduced
horizontal activity. In contrast, fasudil treatment of C57BL6 mice
either had no effect on behavioral outcomes, or improved them.
The maximal force of soleus muscle was reduced in SJL/J mice
treated with fasudil, but the drug had no effect on muscle force in
C57BL6 mice. Lastly, fasudil treated SJL/J mice had fewer F4/80
labeled macrophages/monocytes in skeletal muscle, although
other muscle histology parameters were unchanged.
Evaluation of outcome measures to use in preclinical studies is
an important step toward developing standardized testing
procedures for drug trials of new therapies for the treatment of
muscular dystrophies. As preclinical outcomes for mdx mouse
trials were recently assessed [25], the present paper focuses on a
similar standardized evaluation of commonly used behavioral tests
in dysferlin deficient SJL/J mice, which have been proposed as an
animal model for dysferlin deficient myopathies [8]. The genomic
and histological features of SJL/J mice are fairly well described
[7,9,10,31]. In addition, muscle and trunk weakness have been
observed in SJL/J mice as early as 3 wks of age, when they are
unable to extend their limbs upon suspension by the tail [8].
However, this is the first systematic review of their functional
status, particularly with regard to power analysis for preclinical
pharmacological studies. Functional deficits were detected in
young SJL/J mice that otherwise have no overt symptoms of
disease. Moreover, drug effects were detected as early as 17 wks of
age, and such effects may possibly be detected even earlier, as
significant differences between SJL/J and C57BL6 mice were
apparent as early as 9 wks of age.
Normalized grip strength was a very sensitive indicator of
function and drug effect. Normalized grip strength measurements
have been routinely used to assess disease phenotype as well as
therapeutic efficacy of various agents in the dystrophin deficient
mdx mice [25,30,32]. The effect size calculations in this study
indicate that, as with mdx mice, normalized grip strength is a
reliable outcome measure to study the changes in the disease
phenotype of SJL/J mice. Despite their muscle disease, normalized
forelimb grip strength of the SJL/J mice was significantly greater
than C57BL6 mice at all ages tested (Table 1). This finding is
consistent with a report that showed the strength of young SJL/J
mice was significantly more than Balb/c mice [10]. The reasons
for increased grip strength in dysferlin deficiency are not clear.
Nevertheless, SJL/J mice showed a significant reduction in
normalized grip strength (both fore and hindlimb) between 17
and 25 weeks of age, as also previously observed [10]. This change
in relative strength may be due to the decrease in grip strength
which reflects the progression of the underlying muscle disease, but
also related to the increased weight of the SJL/J mice over time.
Open field measures were among the most sensitive outcome
measures in the SJL/J mouse. This is an important observation
since open field activity tests are relevant to the timed walk test in
humans with neuromuscular disease, which is common clinical
trial endpoint. We observed a significant decrease in the vertical
activity, horizontal activity, and total distance traveled in SJL/J
compared with C57BL6 mice (Table 2). This is correlated to the
significant increase in the rest time in SJL/J compared with
C57BL6 mice. Notably however, there is significant variability in
the sensitivity of different open field parameters, which is reflected
in different effect sizes for horizontal activity, total distance and
vertical activity (34%–89%).
The rotarod was a relatively insensitive test. The latter is
surprising since different rota-rod protocols have been used
successfully with the SJL/J strain in studies of experimental
autoimmune encephalomyelitis, and routinely in studies of motor
neuron degeneration in the B6SJL-Tg (SOD1G93A) 1Gur/J
mouse, but both of these have manipulations that induce much
stronger disease phenotypes (E.g., complete paralysis), than
observed in SJL/J mice [33,34]. Thus, it is possible that the
rota-rod test is not as sensitive to subtle behavioral defects, as are
some of the other measures.
In the present study, the assessments were performed every
8 wks over a 17 wk period-more frequent measurements may
develop a more accurate assessment of subtle functional changes
over time, and detect session-related outliers better. Nevertheless,
more frequent testing will also raise issues with behavioral
adaptation of mice to the testing environment. Thus more work
is needed to determine the optimal testing schedule for assessments
of SJL/J behavior. The present study also evaluated muscle force,
serum creatine kinase and weights of selected muscles as measures
of SJL/J myopathy. Collectively, the reduced muscle force and
increase in creatine kinase observed in SJL/J mice relative to
C57BL6 controls at 25 wks of age suggest ongoing muscle
pathology. These findings are consistent with a previous report
that observed a significant reduction in the specific force of the
tibialis anterior muscle of C57BL/10.SJL-Dysf mice compared to
normal mice [35]. Nevertheless, such degeneration may evolve
selectively, since the soleus and heart muscles in the present study
seemed to be preferentially affected at 25 wks of age. Indeed,
cardiomyopathy has been previously described in other models of
dysferlin deficiency [36]. Elevations of serum CK have also been
observed in dysferlin deficient mice, and are associated with
increasing age [9]. While elevations in serum CK are consistent
with dysferlin deficiency, serum CK levels in our study and others
have large variation, and thus tend to be less useful for small
studies.
The increased spleen weight of SJL/J mice compared to
C57BL6 controls may be associated with the immune/inflamma-
tory dysregulation of these mice, as they have elevated levels of
circulating T cells and are prone to lymphomas with aging [37]. It
is not clear how or even if, these SJL/J characteristics are related
to dysferlin deficiency. Notably, the SJL/J strain has other gene
mutations; in addition to the mutation in dysferlin gene (www.
Jax.org). SJL/J strain also has a unique susceptibility to
autoimmune dysfunction, which makes it useful for models of
multiple sclerosis, encephalitis, myositis, and colitis [38–41]. It also
serves as a background strain in the B6SJL-Tg (SOD1G93A)1-
Gur/J model of amyotrophic lateral sclerosis, which has a faster
progressing form of motor neuron disease than that found in other
mouse strains with the same SOD1 mutation. Moreover the faster
rate of disease progression in this strain is not linked to the
dysferlin deficiency [42]. It is important to recognize these caveats
when attempting to draw associations between the pathobiology of
this strain and that of dysferlin deficient myopathies. Because the
SJL/J mouse is a unique inbred strain, there is no matched control
strain for it, although swiss-derived strains (SWR/J or FVB/J) are
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6 was used as a control strain in the present work because it is the
most widely used general purpose inbred strain, and is commonly
used as a background strain for generation of congenics carrying
spontaneous or induced mutations, as well as for transgenics.
Overall, based on the data from the tests evaluated here, we
suggest that open field and normalized grip strength are probably
the best outcome measures to use for preclinical drug testing in the
SJL/J mice The open field test may be particularly useful, as it is
not likely to be as sensitive to behavioral adaptation (especially if
animals are conditioned to their environment beforehand) as some
of the other tests, and is more amenable to standardization across
laboratories. In addition, the behavioral parameter such as the
total distance (cm) is similar to clinical correlate such as 6 minute
walk test that is used to evaluate drug efficacy human dystrophy
clinical trials.
Both the histopathological data and the behavioral data for grip
strength correlate with other reported results for SJL/J strain. For
example Weller et al., reported 14% reduction in the mean
strength of SJL/J mice between 4 and 6 months of age. The grip
strength of SJL/J mice in our study also showed a comparable
reduction between 4 and 6 months. Further, the behavioral data
showed worsened phenotype at 6 months of age which correlates
with the reported muscle necrosis at 6 months of age in SJL/J mice
[9,10]. However, it should be noted that it is difficult to correlate
behavioral data with gross histological changes because different
techniques were used in different laboratories. Open field testing
has not previously been reported. Further, no one has yet
performed a time course analysis to correlate behavioral data to
the histological change and our study might be the initial step
towards achieving that goal.
Fasudil treatment caused an overall decrease in both forelimb
and hindlimb grip strength of treated SJL/J compared to untreated
SJL/J mice. Fasudil also reduced the horizontal activity of treated
SJL/J mice compared to SJL/J controls. In addition, in vitro force
measurements showed that slow muscle (e.g., soleus) force was
decreased by fasudil (although fast muscle (EDL) force was not).
Together, the data suggest that the continuous administration of
fasudil worsened the disease phenotype in SJL/J mice. The dosage
of fasudil (75 mg/kg) used approaches the high end of published
data for fasudil efficacy after oral administration. The published
doses range from 30–100 mg/kg B.wt [20,26,27]. Keeping the
broad dose range in mind, 75 mg/kg BW was used for the long-
term (16 weeks) study in order to avoid potential toxic effects. Since
it is more than double the minimum effective dose used we assumed
that it would be sufficient to show an effect. Therefore, it is unlikely
that the results reflect inadequate drug levels in the muscle tissue,
although we did not specifically measure it. Conversely, the
detrimental effect is not likely a result of toxicity, because
C57BL6 mice did not show any signs of behavioral deterioration
with treatment at the same dosage.
Our rationale for testing fasudil centered on its potential ability
to inhibit the downstream activation of ROCK by Rho family
GTPases. As Rho-ROCK pathways are activated during phago-
cytosis and cell motility, then treatment with fasudil, in theory,
would reduce the migration of inflammatory cells into muscle. The
histological results support this, as monocyte/macrophage infil-
tration into muscle was reduced by fasudil treatment. Further, this
result is consistent with previously observed reductions of F4/80
+
macrophages, CD4
+, and CD8
+ cells in the glomeruli and the
renal cortex of fasudil administered FcR deficient mice [43].
Histological staining of skeletal muscle of fasudil treated vs
untreated SJL/J mice indicated no differences in regeneration,
degeneration, or muscle fiber injury.
However, it is not clear why fasudil reduced macrophage/
monocyte infiltration, but worsened functional outcomes and
reduced force strength. Previously, we proposed a model whereby
vesicular trafficking, endocytotic proteins, and Rho and Rho
family GTPases are up-regulated in LGMD2B patients and SJL/J
mice to compensate for dysferlin-deficiency. We also proposed that
dysferlin deficiency may lead to decreased expression of immune
regulatory molecules, and thus result in overactive immune
activation and clearance of damaged myofibers. Reduced
macrophage infiltration in fasudil treated muscle clearly indicates
that Rok activation plays an important role in SJL/J inflamma-
tion. However, because the reduction in macrophages was not
associated with improved behavioral outcomes, it raises the
possibility that infiltrating macrophages may, at least in part, be
beneficial to diseased muscle, and that by limiting macrophage
involvement, the disease process is exacerbated. In addition, it is
possible that inhibition of ROCK ameliorated the enhanced
endocytosis and vesicular trafficking that compensate for dysferlin
defiency, and these actions of ROCK might be more important
determinants of muscle pathology than inflammatory status. It is
also possible that inhibition of ROCK prevented activation of
Rok-associated signal transduction cascades that have not
previously been considered in the context of dyferlin-deficient
myopathy [44,45]. Notably, ROCK activation induces apoptosis,
at least in part, through activation of pro-apoptotic pathways and
many studies support that inhibition of ROCK with fasudil
prevents cardiomyocyte apoptosis and related dilated cardiomy-
opathy. Nevertheless, the role of apoptosis, or ROCK, in dysferlin
deficient myopathy, has not been well studied, and remains
uncertain. Alteration of ROCK activity using the rho kinase
inhibitors were reported in multiple different diseases. Further,
fasudil has shown beneficial effects in models of disease involving
non-dysferlin deficient cardiac muscle [46–48]. As rho kinases are
involved in multiple pathways it would be difficult to comment if
the effects of fasudil observed were specific to dysferlin deficiency
In summary, we present behavioral data that provide a basis for
standardization of preclinical drug testing trials in the SJL/J
mouse model of dysferlin deficiency. Open field and normalized
grip strength data were identified as potentially useful longitudinal,
non-invasive measures of functional status, that are potentially
translatable to clinical trial outcomes. In addition, the data suggest
preclinical drug trials can be initiated and/or performed using the
SJL/J model, long before overt muscle damage occurs. Chronic
treatment with the Rho-kinase inhibitor, fasudil worsened
functional outcomes, but also reduced inflammatory cell infiltrates
in diseased SJL/J muscle, which suggests that Rho-kinase may
have a multifactorial role in dysferlin-deficient myopathy.
Supporting Information
Table S1 Comparison of weight, grip strength and rotarod
performance of fasudil treated and untreated C57BL6 mice at 9,
17, and 25 weeks of age.
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DOC)
Table S2 Comparison of open field behavior of fasudil treated
and untreated C57BL/6 mice at 9, 17, and 25 weeks of age.
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Table S3 Histological parameters in the Tibialis Anterior muscle
of fasudil treated and Untreated SJL/J mice at 25 weeks of age.
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